How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,912 results for

physical therapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. External Beam Radiation Therapy Treatment Planning for Clinically Localized Prostate Cancer

to clinicians. The AAPM task group report to provide guidance on the delivery, treatment planning, and clinical implementation of IMRT in 2003 [217]. AAPM Task Group 101 provides guidance on SBRT planning and delivery, including technical aspects of treatment planning and delivery [221]. The ACR Technical Standard for the Performance of Radiation Oncology Physics for External Beam Therapy provides guidance on the required steps of EBRT planning, QA, and delivery [216]. The ACR-ASTRO Practice Parameters (...) External Beam Radiation Therapy Treatment Planning for Clinically Localized Prostate Cancer Date of origin: 1996 Last review date: 2016 ACR Appropriateness Criteria ® 1 External Beam RT Treatment Planning American College of Radiology ACR Appropriateness Criteria ® EXTERNAL BEAM RADIATION THERAPY TREATMENT PLANNING FOR CLINICALLY LOCALIZED PROSTATE CANCER Expert Panel on Radiation Oncology–Prostate: Nicholas G. Zaorsky, MD 1 ; Timothy N. Showalter, MD, MPH 2 ; Gary A. Ezzell, PhD 3 ; Paul L

2016 American College of Radiology

82. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2016.67.1487 Journal of Clinical Oncology - published online before print May 23, 2016 PMID: Endocrine Therapy (...) B. Muss, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; and Harold J. Burstein, Dana-Farber Cancer Center, Boston, MA. H.S.R. and H.J.B. are co-chairs. Abstract Section: Purpose To develop recommendations about endocrine therapy for women with hormone receptor (HR) –positive metastatic breast cancer (MBC). Methods The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of evidence from 2008 through 2015 to create

Full Text available with Trip Pro

2016 American Society of Clinical Oncology Guidelines

83. Hormone Therapy in Postmenopausal Women: Primary Prevention of Chronic Conditions

and physical activity for the prevention of cardiovascular disease in adults who are overweight or obese and have additional cardiovascular disease risk factors. The USPSTF also recommends daily use of low-dose aspirin to decrease the risk of colorectal cancer and cardiovascular disease in appropriate candidates. Other Considerations Research Needs and Gaps Evidence is limited whether the benefits and harms of menopausal hormone therapy vary by age, race/ethnicity, or timing of initiation after menopause (...) Hormone Therapy in Postmenopausal Women: Primary Prevention of Chronic Conditions Final Recommendation Statement: Hormone Therapy in Postmenopausal Women: Primary Prevention of Chronic Conditions - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 11/16/2018 6:27:19 PM You are here: Final Recommendation Statement : Final Recommendation Statement Final Recommendation Statement Hormone Therapy in Postmenopausal Women: Primary Prevention

2017 U.S. Preventive Services Task Force

84. Hormone Therapy in Primary Ovarian Insufficiency

Hormone Therapy in Primary Ovarian Insufficiency Hormone Therapy in Primary Ovarian Insufficiency - ACOG Menu ▼ Hormone Therapy in Primary Ovarian Insufficiency Page Navigation ▼ Number 698, May 2017 Committee on Gynecologic Practice This Committee Opinion was developed by the American College of Obstetricians and Gynecologists’ Committee on Gynecologic Practice in collaboration with committee member Samantha F. Butts, MD, MSCE. This document reflects emerging clinical and scientific advances (...) as of the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Hormone Therapy in Primary Ovarian Insufficiency ABSTRACT: Primary ovarian insufficiency describes a spectrum of declining ovarian function and reduced fecundity due to a premature decrease in initial follicle number, an increase in follicle destruction, or poor follicular response to gonadotropins. The sequelae of primary ovarian insufficiency

2017 American College of Obstetricians and Gynecologists

85. Antenatal Corticosteroid Therapy for Fetal Maturation

Antenatal Corticosteroid Therapy for Fetal Maturation Antenatal Corticosteroid Therapy for Fetal Maturation - ACOG Menu ▼ Antenatal Corticosteroid Therapy for Fetal Maturation Page Navigation ▼ INTERIM UPDATE A correction was published in November 2017 for this title. Click to view the correction. Number 713, August 2017 (Replaces Committee Opinion No. 677, October 2016) (Reaffirmed 2018) Committee on Obstetric Practice This Committee Opinion was developed by the American College (...) Corticosteroid Therapy for Fetal Maturation ABSTRACT: Corticosteroid administration before anticipated preterm birth is one of the most important antenatal therapies available to improve newborn outcomes. A single course of corticosteroids is recommended for pregnant women between 24 0/7 weeks and 33 6/7 weeks of gestation who are at risk of preterm delivery within 7 days, including for those with ruptured membranes and multiple gestations. It also may be considered for pregnant women starting at 23 0/7

2017 American College of Obstetricians and Gynecologists

86. Management of Opioid Therapy (OT) for Chronic Pain

Management of Opioid Therapy (OT) for Chronic Pain VA/DoD CLINICAL PRACTICE GUIDELINE FOR OPIOID THERAPY FOR CHRONIC PAIN Department of Veterans Affairs Department of Defense QUALIFYING STATEMENTS The Department of Veterans Affairs and the Department of Defense guidelines are based upon the best information available at the time of publication. They are designed to provide information and assist decision making. They are not intended to define a standard of care and should not be construed (...) within these guidelines does not guarantee coverage of civilian sector care. Additional information on current TRICARE benefits may be found at www.tricare.mil or by contacting your regional TRICARE Managed Care Support Contractor. Version 3.0 – 201 7V A / D o D Cli ni cal P r a cti ce G ui d el i n e f o r O p ioid T h e r a p y for Ch r on ic Pa in February 2017 Page 2 of 198 Prepared by: The Opioid Therapy for Chronic Pain Work Group With support from: The Office of Quality, Safety and Value, VA

2017 VA/DoD Clinical Practice Guidelines

87. Horticultural Therapy for Children and Adolescents in Residential Treatment for Mental Health

, BS, CTRS, Division of OT/PT/TR in Psychiatry, TRII Ad hoc Members: Margie Hay, Certificate in Horticultural Therapy, Certified Landscape Technician, Master Gardner, Gardner II Division of Psychiatry Senior Clinical Director: Rebecca D. Reder OTD, OTR/L, Division of Occupational Therapy and Physical Therapy Support/Consultant: Mary Ellen Meier MSN, RN, CPN; Center for Professional Excellence and Integration Ad hoc Advisors: Matt Schwendeman MHSA, OTR/L, Division of OT/PT/TR in Psychiatry, Mary (...) Gilene, MBA, Division of Occupational Therapy and Physical Therapy Conflicts of Interest were declared for each team member: No financial conflicts of interest were found. No external funding was received for development of this BESt. The following financial conflicts of interest were disclosed: Therapeutic Recreation/Residential Treatment for Mental Health/Horticultural Therapy/BESt 146 Copyright © 2013 Cincinnati Children's Hospital Medical Center; all rights reserved Page 4 of 5 Note: Full tables

2013 Cincinnati Children's Hospital Medical Center

88. Adjuvant and Salvage Radiation Therapy After Prostatectomy Guideline

Adjuvant and Salvage Radiation Therapy After Prostatectomy Guideline 1 Purpose: The purpose of this guideline is to provide a clinical framework for the use of radiotherapy after prostatectomy in patients with and without evidence of prostate cancer recurrence. Methods: A systematic review of the literature using the Pubmed, Embase and Cochrane databases (search dates 1/1/90 to 12/15/12) was conducted to identify peer-reviewed publications relevant to the use of radiotherapy after prostatectomy (...) . Additional information is provided as Clinical Principles and Expert Opinion when insufficient evidence existed. See text for definitions and detailed information. GUIDELINE STATEMENTS 1. Patients who are being considered for management of localized prostate cancer with radical prostatectomy should be informed of the potential for adverse pathologic findings that portend a higher risk of cancer recurrence and that these findings may suggest a potential benefit of additional therapy after surgery

2013 American Society for Radiation Oncology

89. Pressure Therapy ? Management of Hypertrophic Scarring

Pressure Therapy ? Management of Hypertrophic Scarring Occupational Therapy and Physical Therapy/Hypertrophic Scarring/Pressure Therapy/BESt 176 Best Evidence Statement (BESt) Copyright © 2014 Cincinnati Children's Hospital Medical Center; all rights reserved. Page 1 of 10 Date: March 13, 2014 Title: Use of pressure therapy for management of hypertrophic scarring 1 Clinical Question P (Population/Problem) Among individuals with or at risk for developing active hypertrophic scars* I (...) /svc/alpha/h/health-policy/best.htm, BESt 176, pages 1-10, 3/13/14. Occupational Therapy and Physical Therapy/Hypertrophic Scarring/Pressure Therapy/BESt 176 Copyright © 2014 Cincinnati Children's Hospital Medical Center; all rights reserved. Page 2 of 10 How to use Pressure Therapy 5. It is recommended that pressure therapy appliances* are: a. Used as a prophylactic measure for wounds that take longer than 14 to 21 days to heal, as well as all skin grafts, as these wounds are more likely

2013 Cincinnati Children's Hospital Medical Center

90. British Association of Dermatologists and British photodermatology Group guidelines for topical photodynamic therapy

, Patterson MS. The physics, biophysics and technology of photodynamic therapy. Phys Med Biol 2008; 53:R61–109. 27 Kennedy JC, Marcus SL, Pottier RH. Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): mechanisms and clinical results. J Clin Laser Med Surg 1996; 14:289–304. 28 Enk CD, Levi A. Low-irradiance red LED traf?c lamps as light source in PDT for actinic keratoses. Photodermatol Photoimmunol Pho- tomed 2012; 28:332–4. 29 (...) British Association of Dermatologists and British photodermatology Group guidelines for topical photodynamic therapy GUIDELINE BJD British Journal of Dermatology British Association of Dermatologists and British Photodermatology Group guidelines for topical photodynamic therapy 2018 T.H. Wong, 1 C.A. Morton, 1 N. Collier, 2 A. Haylett, 2 S. Ibbotson, 3 K.E. McKenna, 4 R. Mallipeddi, 5 H. Moseley, 3 D.C. Seukeran, 6 L.E. Rhodes, 2 K.A. Ward, 7 M.F. Mohd Mustapa 8 and L.S. Exton 8 1 Stirling

2019 British Association of Dermatologists

91. Radiation Therapy for the Whole-Breast (ASTRO)

Radiation Therapy for the Whole-Breast (ASTRO) Practical Radiation Oncology (2018) Radiation Therapy for the Whole Breast: An American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline Benjamin D. Smith, MD, a* Jennifer R. Bellon, MD, b Rachel Blitzblau, MD, PhD, c Gary Freedman, MD, d Bruce Haffty, MD, e Carol Hahn, MD, f Francine Halberg, MD, g Karen Hoffman, MD, a Kathleen Horst, MD, h Jean M. Moran, PhD, i Caroline Patton, MA, j Jane Perlmutter, PhD, k Laura Warren, MD, b (...) specific therapy in light of all circumstances presented by the patient. ASTRO assumes no liability for the information, conclusions, and findings contained in its guidelines. This guideline cannot be assumed to apply to the use of these interventions performed in the context of clinical trials. This guideline was prepared on the basis of information available at the time the task force was conducting its research and discussions on this topic. There may be new developments that are not reflected

2019 American Society for Radiation Oncology

92. 2018 IDSA Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy

reliable transportation, availability of a skilled nurse to infuse antimicrobial agents, and all the accompanying office resources but offers additional oversight with daily in-person visits. Another model of OPAT administration occurs in the SNF. Patients with additional nursing needs or no home infusion insurance benefits are typically admitted to a SNF, where on-site nurses perform all infusion functions and other activities such as physical therapy or wound care. Since a SNF is a healthcare (...) 2018 IDSA Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy Outpatient Antimicrobial Parenteral Therapy Search Search 2018 IDSA Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy Published : 13 November 2018 Anne H Norris, Nabin K Shrestha, Genève M Allison, Sara C Keller, Kavita P Bhavan, John J Zurlo, Adam L Hersh, Lisa A Gorski, John A Bosso, Mobeen H Rathore, Antonio Arrieta, Russell M Petrak, Akshay Shah

2018 Infectious Diseases Society of America

93. Barrett's oesophagus: ablative therapy

Barrett's oesophagus: ablative therapy Barrett's oesophagus: ablativ Barrett's oesophagus: ablative ther e therap apy y Clinical guideline Published: 11 August 2010 nice.org.uk/guidance/cg106 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When (...) with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Barrett's oesophagus: ablative therapy (CG106) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 21Contents Contents Introduction 4 Patient-centred care 5 1 Guidance

2010 National Institute for Health and Clinical Excellence - Clinical Guidelines

94. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV

Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV GUIDELINE ON WHEN TO START ANTIRETROVIRAL THERAPY AND ON PRE-EXPOSURE PROPHYLAXIS FOR HIV SEPTEMBER 2015 GUIDELINESThis early-release guideline will form part of the updated WHO consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection due to be published in 2016.GUIDELINE ON WHEN TO START ANTIRETROVIRAL THERAPY AND ON PRE-EXPOSURE PROPHYLAXIS FOR HIV SEPTEMBER (...) 2015WHO Library Cataloguing-in-Publication Data Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. 1.HIV Infections – drug therapy. 2.Anti-Retroviral Agents – administration and dosage. 3.Anti-Retroviral agents – therapeutic use. 4.Time-to-Treatment. 5.Guideline. I.World Health Organization. ISBN 978 92 4 150956 5 (NLM classification: WC 503.2) © World Health Organization 2015 All rights reserved. Publications of the World Health Organization are available

2015 World Health Organisation HIV Guidelines

95. Guidance on couples HIV testing and counselling - including antiretroviral therapy for treatment and prevention in serodiscordant couples

Guidance on couples HIV testing and counselling - including antiretroviral therapy for treatment and prevention in serodiscordant couples For more information, contact: World Health Organization Department of HIV/AIDS 20, avenue Appia 1211 Geneva 27 Switzerland E-mail: hiv-aids@who.int http://www.who.int/hiv/en/ ISBN 978 92 4 1501972 hiv/aids Programme April 2012 GUIDANCE ON COUPLES HIV TESTING AND COUNSELLING INCLUDING ANTIRETROVIRAL THERAPY FOR TREATMENT AND PREVENTION IN SERODISCORDANT (...) COUPLES Recommendations for a public health approachhiv/aids Programme April 2012 GUIDANCE ON COUPLES HIV TESTING AND COUNSELLING INCLUDING ANTIRETROVIRAL THERAPY FOR TREATMENT AND PREVENTION IN SERODISCORDANT COUPLES Recommendations for a public health approachWHO Library Cataloguing-in-Publication Data Guidance on couples HIV testing and counselling including antiretroviral therapy for treatment and prevention in serodiscordant couples: recommendations for a public health approach. 1.HIV infections

2012 World Health Organisation HIV Guidelines

96. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours GUIDELINES The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours John J. Zaknun & L. Bodei & J. Mueller-Brand & M. E. Pavel & R. P. Baum & D. Hörsch & M. S. O’Dorisio & T. M. O’Dorisiol & J. R. Howe & M. Cremonesi & D. J. Kwekkeboom # The Author(s) 2013. This article is published with open access (...) at Springerlink.com Abstract Peptidereceptorradionuclidetherapy(PRRNT)isa molecularly targeted radiation therapy involving the systemic administrationofaradiolabelledpeptidedesignedtotargetwith high affinity and specificity receptors overexpressed on tumours. PRRNTemploying the radiotagged somatostatin re- ceptoragonists 90 Y-DOTATOC([ 90 Y-DOTA 0 ,Tyr 3 ]-octreotide) or 177 Lu-DOTATATE ([ 177 Lu-DOTA 0 ,Tyr 3 ,Thr 8 ]-octreotideor [ 177 Lu-DOTA 0 ,Tyr 3 ]-octreotate) have been successfully used for the past 15

2013 European Association of Nuclear Medicine

97. Stem Cell Therapies in Obstetrics and Gynaecology

Stem Cell Therapies in Obstetrics and Gynaecology Stem Cell Therapies in Obstetrics and Gynaecology: The Female Urogenital T ract and the Fetus as Sources and T argets for Molecular and Regenerative Medicine Scientific Impact Paper No. 38 May 2013Stem Cell Therapies in Obstetrics and Gynaecology: The Female Urogenital Tract and the Fetus as Sources and Targets for Molecular and Regenerative Medicine This is the first edition of this paper. 1. Introduction Reproductive tissues are now recognised (...) . In the field of gynaecology, regenerative medicine approaches to repair or replace damaged or diseased urogenital tract organs, such as the urinary sphincter, pelvic floor, uterus, ovaries and vagina, are currently in the preclinical and clinical phases of study. In obstetrics, the area of stem cell transplantation has been largely focused on fetal therapy. 2. Stem cells from reproductive tissues Over the past decade, stem cells have been isolated from embryonic, fetal and extra–fetal tissues, as well

2013 Royal College of Obstetricians and Gynaecologists

98. Position statement on the use of antiretroviral therapy to reduce HIV transmission

Position statement on the use of antiretroviral therapy to reduce HIV transmission Position statement on the use of antiretroviral therapy to reduce HIV transmission, January 2013: The British HIV Association (BHIVA) and the Expert Advisory Group on AIDS (EAGA) S Fidler, 1 J Anderson, 2 Y Azad, 3 V Delpech, 4 C Evans, 5 M Fisher, 6 B Gazzard, 5 N Gill, 4 L Lazarus, 4 R Lowbury, 7 K Orton, 8 B Osoro, 9 K Radcliffe, 10 B Smith, 11 D Churchill, 6 K Rogstad 12 and G Cairns 13 1 Imperial College (...) Hospital, Shef?eld, UK and 13 NAM Publications/Aidsmap.com, London, UK Accepted 6 February 2013 De?nition: This statement refers to the use of antiretroviral therapy (ART) by HIV-positive individuals to reduce the risk of transmission of HIV. 1 There is now conclusive randomized clinical trial evi- dence, from heterosexual couples where one partner has HIV infection and the other does not, that if the partner who is HIV positive is taking effective ART, transmission of HIV through vaginal sex is signi

2013 Publication 4880703

99. Guidelines for 131I - ethiodised oil [Lipiodol] Therapy

is a beta emitting radionuclide with a physical half life of 8.04 days. The maximum and mean beta particle energies are 0.61MeV and 0.192MeV respectively. 131 I emits a principal gamma photon of 364 keV (81% abundance). 2. Ethiodised oil, also known as Lipiodol is a naturally iodinated fatty acid ethyl ester of poppy seed oil. 3. Therapy in this context means the intra-arterial administration of 131 I-Lipiodol. B. BackgroundAfter hepatic intra-arterial injection, 131 I-Lipiodol follows arterial flow (...) Guidelines for 131I - ethiodised oil [Lipiodol] Therapy GUIDELINES FOR 131 I - ETHIODISED OIL [LIPIODOL] THERAPY I. PURPOSE The purpose of this guideline is to assist nuclear medicine practitioners in: 1. evaluating patients who might be candidates for treatment using 131 I lipiodol for primary hepatocellular carcinoma. 2. providing information for performing this treatment 3. understanding and evaluating the sequelae of therapy II. BACKGROUND INFORMATION AND DEFINITIONS A. Definitions 1. 131 I

2002 European Association of Nuclear Medicine

100. EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy

tumours 2. Provide information for performing this treatment 3. Understand and evaluate the consequences of therapy Background information and definitions Definitions The following are the definitions in this guideline: 1. 131 I is a beta-emitting radionuclide with a physical half- lifeof8.04days,aprincipalgammarayof364KeV(81% abundance)andbetaparticleswithamaximumenergyof 0.61 MeVandan average energyof 0.192 Mev. 2. mIBG or Iobenguane is an aralkylguanidine resulting from the combination (...) . The administration of 131 I should be undertaken by appropriately trained medical staff with supporting nursing staff and available medical physics expert (according to European directive EURATOM 97/43) [7]. Physicians responsible for treating patients should have anunderstandingoftheclinicalpathophysiologyandnatural history of the disease processes, should be familiar with 1040 Eur J Nucl Med Mol Imaging (2008) 35:1039–1047other forms of therapy, and should be able to liaise closely with other physicians

2008 European Association of Nuclear Medicine

Guidelines

Guidelines – filter by country